Neuroimaging

Lecanemab named one of the world's best inventions in 2023 by TIME

Retrieved on: 
tisdag, oktober 24, 2023
Risk, Aneurysm, Vomiting, Cerebral edema, Focal neurologic signs, Incidence, Dementia, Nausea, Disease, Intraparenchymal hemorrhage, Intracerebral hemorrhage, CET, Chills, AI, Paracetamol, Hypersensitivity, Memory, Lecanemab, Vascular malformation, MRI, Excipient, Neuroimaging, Fatal, Thought, Dizziness, Aspirin, Edema, Anticoagulant, Cerebral amyloid angiopathy, Magnetic resonance imaging, Patient, Bronchospasm, Alzheimer's disease, Anaphylaxis, Genetic testing, TIME, ARIA, Arthralgia, Research, Eisai, Fever, Hypotension, Amyloid, Headache, Siderosis, Behavior, Invention, Observation, Hypertension, Confusion, Seizure, Angioedema, Status epilepticus, Tissue plasminogen activator, Pharmaceutical industry, Lace, Medical imaging, Copper

"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.

Key Points: 
  • "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.
  • TIME's annual list of the best inventions includes "200 extraordinary innovations changing lives."
  • The information was released for public disclosure, through the agency of the contact persons below, on October 24, 2023, at 4.50 p.m. CET.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.

Alzheimer's Drug Discovery Foundation (ADDF) Announces Launch of SpeechDx, the First Study to Generate a Voice Database Paired with Clinical Data for Early Detection of Alzheimer's Disease

Retrieved on: 
måndag, oktober 23, 2023
Fillit, Intelligence, Speech, Alzheimer's Drug Discovery Foundation, Neuroimaging, Biomarker, Gates Ventures, Human, Data, MD, Health, Doctor of Philosophy, Entrepreneurship, Dementia, Research, Tablet, BBRC, Disease, Ace, Machine learning, Emory University, Boston University, Brain, Algorithm, Language, Collection, Diagnosis, Dual-energy X-ray absorptiometry, Pharmaceutical industry, Medical imaging, Mobile phone, Alzheimer's disease

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.

Key Points: 
  • SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms.
  • Study participants will be given handheld tablets with the pre-installed SpeechDx app to capture their voice data.
  • The use of this warehouse of data will be fundamental for the development of new and renewable digital voice biomarkers.
  • Additionally, each participant's voice recording will be paired with clinical data and harmonized across all sites.

Self-Injurious Thoughts & Behaviors in Youth - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
torsdag, oktober 5, 2023
Brain & Behavior Research Foundation, Mental health service, Brain, University, Neuroimaging, Mental, Neuroscience, Assistant, Suicidal ideation, Interior design, Toy

New York, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Self-Injurious Thoughts & Behaviors in Youth” on Tuesday, October 10, 2023, at 2:00 pm ET.

Key Points: 
  • New York, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Self-Injurious Thoughts & Behaviors in Youth” on Tuesday, October 10, 2023, at 2:00 pm ET.
  • The webinar will be hosted by Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds.
  • Self-injurious thoughts and behaviors (SITBs) refer to thoughts and behaviors involving suicidal intent (suicidal ideation, plans, and behaviors) as well as deliberate self-injury in the absence of any intent to die.
  • Mental health services for youth who experience SITBs are often limited, with crisis lines being among the most easily accessible support.

Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives

Retrieved on: 
tisdag, oktober 10, 2023
Radiology, Health, Medical Devices, Neuroscience, University School, DRS, SUNY Downstate Medical Center, Senior, Neuroradiology, Google Images, Stroke, Politics, Society, Book, University, Emory University, Injury, Gary Knopp, Davos, Neuroimaging, American Board of Commissioners for Foreign Missions, FDA, Georgetown University, American Board of Radiology, Philips, Medical imaging, Nursing, Biology, Medtronic, Hyperfine structure, Science

Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.

Key Points: 
  • Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.
  • Dr. Knopp joined Hyperfine, Inc. in 2021 and brings three decades of experience in radiology, neuroradiology, and MR imaging.
  • In the role of vice president of scientific affairs, Dr. Chip Truwit will spearhead clinical innovation projects, supporting the Swoop® system’s continued advancement.
  • Dr. Chip Truwit joined Hyperfine, Inc. in 2022 and has over three decades of experience in academic and clinical radiology.

Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Retrieved on: 
måndag, oktober 9, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Houston Methodist Hospital, Cerebrospinal fluid, DRS, Biomarker, LD, Coya, COYA, Safety, Neuroimaging, Bill & Melinda Gates Foundation, ADAS-Cog, SD, Therapy, MMSE, Dementia, AD, Melinda French Gates, Blood, Regulatory T cell, Patient, Pharmaceutical industry

A total of 38 patients were randomly assigned to receive subcutaneous LD IL-2 at two different dosing regimens, or matching placebo, over 21 weeks.

Key Points: 
  • A total of 38 patients were randomly assigned to receive subcutaneous LD IL-2 at two different dosing regimens, or matching placebo, over 21 weeks.
  • Coya previously reported that the treatment with LD IL-2 significantly expanded Treg population and function in an open-label proof-of concept study in 8 patients with AD.
  • Overall, administration of LD IL-2 appeared to be well tolerated in the 8 patients in the open-label, proof-of concept study.
  • No serious adverse events were reported, and no patient discontinued the study.

New Findings: Multi-Year Scientific Study Reveals Playing With Dolls Allows Children to Develop and Practice Social Skills, Regardless of Their Neurodevelopmental Profile

Retrieved on: 
torsdag, september 28, 2023
Retail, General Entertainment, Mental Health, Neurology, Children, Clinical Trials, Supermarket, People with Disabilities, Specialty, Science, Entertainment, Consumer, Health, Research, Toys, Quotient, Partnership, Parent, Social skills, Neuroimaging, Language, Wales Autism Research Centre, Multimedia, Brain, Emotion, Cardiff, Cardiff University, Spectrum, Tablet, Creativity, Mattel Inc v 3894207 Canada Inc, Year 3 (artwork), Autism spectrum, Child, European Journal of Neuroscience, Empathy, Ageing, PSTS Tanjungbalai, European Journal, Caregiver, Toy, Mattel

The results from the third year reinforce this finding across children with and without high levels of autistic traits, albeit through their different approaches to play.

Key Points: 
  • The results from the third year reinforce this finding across children with and without high levels of autistic traits, albeit through their different approaches to play.
  • “Our study shows that doll play can encourage social processing in children, regardless of their neurodevelopmental profile.
  • The study's results suggest that doll play could support social processing, regardless of a child’s neurodevelopmental profile, but through different pathways.
  • The Year 3 findings from Cardiff University indicate that children, regardless of their neurodevelopmental profile, can play with and potentially benefit from play with dolls in terms of their social development.

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

Retrieved on: 
måndag, september 25, 2023
Hypersensitivity, Status epilepticus, Intracerebral hemorrhage, Cerebral amyloid angiopathy, Arthralgia, Cerebral edema, Hypotension, Aneurysm, Risk, Focal neurologic signs, Chills, Fatal, Fever, Edema, Neuroimaging, AND, Angioedema, Siderosis, Tissue plasminogen activator, Aspirin, Hypertension, Vomiting, Incidence, Excipient, ARIA, Anticoagulant, MRI, Magnetic resonance imaging, Dizziness, Amyloid, Patient, Intraparenchymal hemorrhage, Anaphylaxis, Paracetamol, Seizure, Genetic testing, Confusion, Nausea, Observation, Lecanemab, Headache, Bronchospasm, Vascular malformation, Medical device, Pharmaceutical industry, Lace, Medical imaging, Copper

INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.

Key Points: 
  • INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.
    LEQEMBI is indicated for the treatment of Alzheimer’s disease.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Driven Data and HeroX Tapped to Enhance Crowdsourcing Challenge for Early Detection of Alzheimer's and Related Dementias

Retrieved on: 
torsdag, september 7, 2023
National Institute on Aging, NIA, Neuroimaging, Dementia, Research, Biomarker, Eligibility, Bangladesh Technical Education Board, Alzheimer's disease, Explainable artificial intelligence, Patient, Algorithm, Challenge, Diagnosis, EUREKA, Behavior, Risk management, Pharmaceutical industry, Medical imaging, Prize

BOULDER, Colo., Sept. 7, 2023 /PRNewswire/ -- DrivenData, the hub of data science competitions that advance solutions for social good, will support the National Institute on Aging (NIA)'s crowdsourced prize competition PREPARE: Pioneering Research for Early Prediction of Alzheimer's and Related dementias EUREKA Challenge. HeroX, the social network for innovation and the world's leading platform for crowdsourced solutions, will serve as an additional collaborator. The challenge aims to spur and reward the development of solutions for accurate, innovative, and representative early prediction of Alzheimer's disease and related dementias.

Key Points: 
  • The challenge aims to spur and reward the development of solutions for accurate, innovative, and representative early prediction of Alzheimer's disease and related dementias.
  • "Alzheimer's and related dementias affect millions of patients and families," said Greg Lipstein, principal, DrivenData.
  • "This challenge is a powerful opportunity to leverage advances in data and AI to equip care teams with greater capabilities for early prediction."
  • Early intervention will likely be important for successful disease modification, but detecting early signs of cognitive decline and Alzheimer's and related dementias is challenging.

BrainTale Presented the Real-life Usage Potential of Its Biomarkers Technology During the 35th Eastern NeuroRadiology Society Conference

Retrieved on: 
torsdag, augusti 31, 2023
Health, Neurology, General Health, Research, Science, Pharmaceutical, Biotechnology, Magnetic resonance imaging, DTI, MGH, Hospital, Neuroimaging, Ageing, Diffusion, Brain, Biomarker, Brain damage, Associate, Harvard Medical School, MRI, ENRS, Patient, Myenteric plexus, Physician, Neuroradiology, Mass General Brigham, White matter, Massachusetts General Hospital, ALS, Calibration, Medical imaging

Accordingly, since its creation in 2018, BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases.

Key Points: 
  • Accordingly, since its creation in 2018, BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases.
  • Over the past three decades, diffusion tensor imaging (DTI) technology has demonstrated its ability to detect subtle changes in the microstructure of white matter.
  • Quantification and standardization of data is mandatory to enable reliable interpretation and real-life decision-making based on the assessment of white matter integrity.
  • Professor Rajiv Gupta presented the poster entitled "Integration of Diffusion Tensor biomarkers into clinical routine" on Friday August 25th.

Cybin Reports First Quarter Financial Results and Recent Business Highlights

Retrieved on: 
måndag, augusti 14, 2023
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Inc., Partnership, Therapy, Nature Portfolio, Cohort, Neuroimaging, Open access, MDD, Scientific Reports, NYSE, Safety, Worldwide, NEO, Pharmaceutical industry, Vaccine

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported unaudited financial results for its first quarter ended June 30, 2023, and recent business highlights.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today reported unaudited financial results for its first quarter ended June 30, 2023, and recent business highlights.
  • The recent marketed public offering further strengthens our position to deliver on these value-driving milestones,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • “I am proud of the Cybin team’s thoughtful approach and strategic decisions that have enabled us to accelerate our clinical-stage programs.
  • Cash flows used in operating activities were C$10.7 million for the quarter ended June 30, 2023, compared to C$11.1 million in the same period last year.